Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 7/20 | 0.51 |
| ▸ | CTSS | P25774 | 6/20 | 0.51 |
| ▸ | CTSL | P07711 | 5/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2913071 | 1.00 | SLC7A5 (0.52) | SLC7A5CTSKCTSSCTSLCTSB | |
| SCHEMBL17152541 | 0.84 | ANPEP (0.44) | SLC7A5CTSKCTSSCTSLCTSB | |
| SCHEMBL10572975 | 0.82 | SLC7A5 (0.54) | SLC7A5 | |
| SCHEMBL10572972 | 0.82 | SLC7A5 (0.54) | SLC7A5 | |
| Water SCHEMBL25363515 | 0.81 | SLC7A5 (0.52) | SLC7A5 | |
| SCHEMBL15412847 | 0.81 | SLC7A5 (0.52) | SLC7A5CTSS | |
| Water SCHEMBL25363513 | 0.81 | SLC7A5 (0.52) | SLC7A5 | |
| SCHEMBL19882812 | 0.79 | — | — | |
| SCHEMBL13789959 | 0.79 | SLC7A5 (0.54) | SLC7A5 | |
| SCHEMBL16307349 | 0.79 | SLC7A5 (0.50) | SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256743-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2014-09-11 | — | — | US | claimed |
| US-8772336-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2014-07-08 | — | — | US | claimed |
| US-20130035312-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS | AXYS PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | US | claimed |
| US-8318748-B2 | Cathepsin cysteine protease inhibitors | Merck, Sharp & Dohme Corp. (US) | 2012-11-27 | — | — | US | claimed |
| US-20110230446-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | claimed |
| US-7973037-B2 | Cathepsin cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | claimed |
| EP-1841419-A4 | CATHEPSIN K INHIBITORS AND OBESITY | MERCK FROSST CANADA LTD (CA) | 2009-02-25 | — | — | EP | claimed |
| US-20090005323-A1 | Cathepsin K Inhibitors and Obesity | MERCK FROSST CANADA LTD. (CA) | 2009-01-01 | — | — | US | claimed |
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2008-08-07 | — | — | US | claimed |
| US-20080125442-A1 | Cathepsin K Inhibitors and Atherosclerosis | MERCK FROSST CANADA LTD. (CA) | 2008-05-29 | — | — | US | claimed |
| EP-1482924-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2006-03-08 | — | — | EP | claimed |
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2005-10-27 | — | — | US | claimed |
| EP-1372655-A4 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2005-10-12 | — | — | EP | claimed |
| EP-1572667-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | claimed |
| EP-1482924-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2004-12-08 | — | — | EP | claimed |
| WO-2004054987-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | WO | claimed |
| EP-1372655-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-01-02 | — | — | EP | claimed |
| US-20030232863-A1 | Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders | BAYLY CHRISTOPHER I (CA) | 2003-12-18 | — | — | US | claimed |
| WO-2003075836-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-09-18 | — | — | WO | claimed |
| WO-2002069901-A2 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2002-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035312-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS | CTSB, CTSS, CTSZ | SLC7A5 829/4885CTSK 4/4885CTSS 2/4885 |
| US-20140256743-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | SLC7A5 410/4885CTSK 4/4885CTSS 2/4885 |
| US-20030232863-A1 | Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders | CTSE, CTSB, CTSS | SLC7A5 653/4885CTSK 4/4885CTSS 3/4885 |
| US-20080125442-A1 | Cathepsin K Inhibitors and Atherosclerosis | CTSK, CTSD, CTSS | SLC7A5 3143/4885CTSK 1/4885CTSS 3/4885 |
| US-20110230446-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | SLC7A5 410/4885CTSK 4/4885CTSS 2/4885 |
| US-20090005323-A1 | Cathepsin K Inhibitors and Obesity | CTSK, CTSG, CTSB | SLC7A5 2729/4885CTSK 1/4885CTSS 7/4885 |
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | CTSE, CTSL, CTSK | SLC7A5 685/4885CTSK 3/4885CTSS 6/4885 |
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | CTSE, CTSS, CTSB | SLC7A5 566/4885CTSK 4/4885CTSS 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.